(NASDAQ: CGC) Canopy Growth's forecast annual revenue growth rate of 4.8% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 4.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.68%.
Canopy Growth's revenue in 2025 is $192,139,285.On average, 3 Wall Street analysts forecast CGC's revenue for 2026 to be $36,914,918,796, with the lowest CGC revenue forecast at $35,855,063,778, and the highest CGC revenue forecast at $38,569,981,577. On average, 2 Wall Street analysts forecast CGC's revenue for 2027 to be $38,700,542,085, with the lowest CGC revenue forecast at $38,494,052,771, and the highest CGC revenue forecast at $38,907,031,399.
In 2028, CGC is forecast to generate $41,160,820,595 in revenue, with the lowest revenue forecast at $41,160,820,595 and the highest revenue forecast at $41,160,820,595.